Researchers from the University of Minnesota will conduct an oral presentation on their recent human clinical trial using Pantesin®. The presentation will be made during the American Heart Association's Scientific Session on Nutrition and Cardiovascular Diseases, to be held November 8 at the Ernest N. Morial Convention Center in New Orleans.
Pantesin® is a high quality pharmaceutical grade form of pantethine sold exclusive by Daiichi Fine Chemicals, Inc.
The study, led by Joe Keenan, M.D. and Joel J. Pins, is entitled “Pantethine beneficially affects apolipoprotein A-1, apolipoprotein B, low density lipoprotein particle size but not high-sensitivity C-Reactive protein in a dyslipidemic population.”
For more information, visit www.pantesin.com.